Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia

Journal of Clinical Oncology

Volumn 20, Issue 20, 2002, Pages 4217-4224

  Crews, Kristine R ^a   Gandhi, Varsha ^a   Srivastava, Deo Kumar ^a   Razzouk, Bassem I ^a   Tong, Xin ^a   Behm, Fred G ^a   Plunkett, William ^a   Raimondi, Susana C ^a   Pui, Ching Hon ^a   Rubnitz, Jeffrey E ^a   Stewart, Clinton F ^a   Ribeiro, Raul C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; CYTARABINE; CYTARABINE TRIPHOSPHATE; DAUNORUBICIN; ETOPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG INFUSION; DRUG RESPONSE; FEMALE; HUMAN; INFANT; MALE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; REMISSION INDUCTION;

EID: 0037108698     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.10.006     Document Type: Article

References (34)

1. Woods WG, Kobrinsky N, Buckley JD, et al: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989, 1996
2. Ravindranath Y, Yeager AM, Chang MN, et al: Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group. N Engl J Med 334:1428-1434, 1996
3. Arnaout MK, Radomski KM, Srivastava DK, et al: Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: Short- and long-term effects. Leukemia 14:1736-1742, 2000
4. Krance RA, Hurwitz CA, Head DR, et al: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19:2804-2811, 2001
5. Stevens RF, Hann IM, Wheatley K, et al: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML trial - MRC Childhood Leukaemia Working Party. Br J Haematol 101:130-140, 1998
6. Creutzig U, Ritter J, Zimmermann M, et al: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 19:2705-2713, 2001
7. Woods WG, Neudorf S, Gold S, et al: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 97:56-62, 2001
8. Momparler RL, Fischer GA: Mammalian deoxynucleoside kinase: I. Deoxycytidine kinase: Purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 243:4298-4304, 1968
9. Gandhi V, Estey E, Keating MJ, et al: Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124, 1993
10. Avramis VI, Wiersma S, Krailo MD, et al: Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias: The Children's Cancer Group. Clin Cancer Res 4:45-52, 1998
11. Gandhi V, Plunkett W: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329-334, 1988
12. Gandhi V, Nowak B, Keating MJ, et al: Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74:2070-2075, 1989
13. Gandhi V, Kemena A, Keating MJ, et al: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897-903, 1992
14. Santana VM, Mirro J Jr, Kearns C, et al: 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 10:364-370, 1992
15. Santana VM, Hurwitz CA, Blakley RL, et al: Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237-1242, 1994
16. Kornblau SM, Gandhi V, Andreeff HM, et al: Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 10:1563-1569, 1996
17. Gandhi V, Estey E, Keating MJ, et al: Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 87:256-264, 1996
18. Plunkett W, Hug V, Keating MJ, et al: Quantitation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 40:588-591, 1980
19. Gandhi V, Danhauser L, Plunkett W: Separation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and 9-beta-D-arabinofurano-syl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr 413:293-299, 1987
20. Estey E, Plunkett W, Dixon D, et al: Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1:580-583, 1987
21. Plunkett W, Nowak B, Keating MJ: Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep 71:479-483, 1987
22. Plunkett W, Iacoboni S, Estey E, et al: Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol 12:20-30, 1985
23. Plunkett W, Liliemark JO, Adams TM, et al: Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005-3011, 1987
24. Gandhi V, Nowak B, Keating MJ, et al: Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 74:2070-2075, 1989
25. Gandhi V, Estey E, Keating MJ, et al: Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10:109-114, 1993 (suppl)
26. Santana VM, Mirro J Jr, Harwood FC, et al: A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 9:416-422, 1991.
27. Liliemark J, Juliusson G: On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 51:5570-5572, 1991
28. Liliemark J, Juliusson G: Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1:385-390, 1995
29. Larson RA, Mick R, Spielberger RT, et al: Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol 14:188-195, 1996
30. Arnaout MK, Radomski KM, Srivastava DK, et al: Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: Short-and long-term effects. Leukemia 14:1736-1742, 2000
31. Liliemark JO, Plunkett W, Dixon DO: Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1 -beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res 45:5952-5957, 1985
32. Heinemann V, Estey E, Keating MJ, et al: Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 7:622-628, 1989
33. Creutzig U, Zimmermann M, Ritter J, et al: Definition of a standardrisk group in children with AML. Br J Haematol 104:630-639, 1999
34. Creutzig U, Ritter J. Zimmermann M, et al: Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93 - AML-BFM Study Group. Leukemia 15:348-354, 2001